


High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment

Amrei von Braun^{1,2*}, Barbara Castelnuovo¹, Bruno Ledergerber², Jessica Cusato³, Allan Buzibye¹, Andrew Kambugu¹, Jan Fehr^{2,4}, Andrea Calcagno ³, Mohammed Lamorde¹ and Christine Sekagya-Wiltshire¹

¹Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda; ²Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; ³Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy; ⁴Department of Public Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland

*Corresponding author. Present address: Division of Infectious Diseases and Tropical Medicine, Leipzig University Hospital, Liebigstrasse 20, 04103 Leipzig, Germany. Tel: +49-341-9720017; Fax: +49-341-9724979; E-mail: amrei.braun@medizin.uni-leipzig.de

Received 27 April 2018; returned 26 June 2018; revised 5 August 2018; accepted 24 August 2018

Objectives: To report the efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults on concomitant anti-TB treatment and analyse factors associated with elevated concentrations in this specific population.

Methods: Serum efavirenz concentrations in TB/HIV-coinfected Ugandan adults on efavirenz-based ART (600 mg daily) were measured onsite at 2, 8, 12 and 24 weeks of concomitant anti-TB treatment, including rifampicin. Genetic analysis was done retrospectively through real-time PCR by allelic discrimination (CYP2B6 516G>T, rs3745274). Univariable and multivariable logistic regression analyses were done to assess factors potentially associated with elevated efavirenz serum concentrations.

Results: A total of 166 patients were included in the analysis. The median age was 34 (IQR = 30–40) years, 99 (59.6%) were male, the median CD4 cell count was 195 (IQR = 71–334) cells/mm³ and the median BMI was 19 (IQR = 17.6–21.5) kg/m². Almost half of all patients (82, 49.4%) had at least one efavirenz serum concentration above the reference range of 4 mg/L. The serum efavirenz concentrations of patients with genotype CYP2B6 516 TT were consistently above 4 mg/L and significantly higher than those of patients with GG/GT genotypes: CYP2B6 516 TT 9.6 mg/L (IQR = 7.3–13.3) versus CYP2B6 516 GT 3.4 mg/L (IQR = 2.1–5.1) and CYP2B6 516 GG 2.6 mg/L (IQR = 1.3–4.0) (Wilcoxon rank-sum test: $P < 0.0001$).

Conclusions: A large proportion of our study participants had at least one efavirenz serum concentration >4 mg/L. The CYP2B6 516 TT genotype was the strongest predictor of high concentration. Physicians should be vigilant that efavirenz serum concentrations may be elevated in patients on concomitant anti-TB treatment and that individualized care is warranted whenever possible.

Introduction

In 2016, the WHO reported 44 816 new cases of TB in Uganda, of which 51% were coinfecting with HIV, ranking the country among the top 20 high-burden countries for TB/HIV coinfection.¹

HIV-infected patients diagnosed with TB are preferably treated with efavirenz-based ART at a dose of 600 mg daily despite complex drug–drug interactions with rifampicin-based anti-TB treatment.² Efavirenz is known for its neuropsychological side effects,³ predominantly occurring in patients with serum drug levels above the reference range.^{4,5} High efavirenz serum concentrations are associated with slow metabolism due to SNPs at positions 516 and 983 of the cytochrome P450 (CYP) 2B6 gene, which occur more

frequently in the African population [frequency of 18% according to HapMap-YRI (sub-Saharan African)].⁶

As a potent inducer of CYP2B6, the additional influence of rifampicin on efavirenz concentrations is complex. Previous studies reported a decrease in efavirenz concentrations,⁷ while others found no evidence of reduced efavirenz exposure in the presence of rifampicin,⁸ resulting in an ongoing discussion on efavirenz dose reduction. Furthermore, as standard first-line anti-TB treatment includes isoniazid as well, it should be mentioned that the potential inducing effect of rifampicin may be counterbalanced by the concentration-dependent inhibitory effect of isoniazid on efavirenz clearance.⁹

A randomized clinical trial demonstrated non-inferiority of an efavirenz dose of 400 versus 600 mg.¹⁰ However, patients coinfecting with TB were not included in the study. A previous study from Uganda that enrolled 158 TB/HIV-coinfecting patients showed that simulated AUCs for a 600 mg efavirenz dose were 1.2 and 2.4 times greater than the product label for study participants in general and *CYP2B6* genotypes, respectively.¹¹ According to the authors, efavirenz daily doses of 450 and 250 mg for HIV-infected Ugandans in general and individuals homozygous for *CYP2B6**6 genotypes receiving rifampicin co-treatment, respectively, yielded simulated exposures comparable to the product label.

Further research on treatment optimization in TB/HIV-coinfecting patients is needed. We report here the pharmacokinetic and pharmacogenetic data from a clinical cohort study on TB/HIV-coinfecting Ugandan adults and assess factors associated with elevated serum efavirenz concentrations in this specific population.

Methods

Between June 2013 and November 2015, pharmacokinetic data of TB/HIV-coinfecting patients on rifampicin-based anti-TB therapy and ART including 600 mg of efavirenz was prospectively collected at the integrated TB/HIV clinic of the Infectious Diseases Institute in Kampala, Uganda. All patients were above the age of 18 years and participants in a clinical trial, with signed informed consent.^{12,13} Serum efavirenz concentrations were measured onsite using a validated UV-HPLC method after 2, 8 and 24 weeks of anti-TB therapy. For patients requiring an extended intensive TB treatment phase of 12 weeks, serum efavirenz concentrations were additionally measured at week 12. Genetic analysis was done onsite retrospectively through real-time PCR by allelic discrimination (*CYP2B6* 516G>T, rs3745274).

Characteristics of study participants (age, gender, weight, BMI, CD4 cell count, haemoglobin, creatinine and ALT) with at least one efavirenz serum concentration above the upper limit of 4 mg/L were compared with those with concentrations within the reference range (1–4 mg/L)⁵ using the Wilcoxon rank-sum test. To assess factors potentially associated with elevated efavirenz serum concentrations, covariates were further investigated by univariable and multivariable logistic regression analyses using generalized estimating equations to account for multiple measurements per patient. These analyses were restricted to patients with available *CYP2B6* genotype and included age (per 10 years older), gender and weight (per 10 kg higher). Haemoglobin was strongly correlated with weight and therefore omitted.

This study was reviewed and approved by the Makerere University School of Medicine Research and Ethics Committee (Approval number: 120-2009) and the Uganda National Council for Science and Technology (HS 683).

Results

A total of 166 TB/HIV-coinfecting patients on efavirenz-based ART and concomitant anti-TB treatment with at least one efavirenz serum measurement during anti-TB treatment and available *CYP2B6* genotype were included in this analysis. The median age was 34 (IQR = 30–40) years, 99 (59.6%) were male, the median CD4 cell count was 195 (IQR = 71–334) cells/mm³ and the median BMI was 19 (IQR = 17.6–21.5) kg/m². Most patients (134, 80.7%) were ART naive at TB diagnosis and started on an efavirenz-based regimen 2 weeks after initiation of anti-TB therapy. Twenty-nine patients (17.5%) were already on efavirenz when anti-TB treatment was initiated, while three (1.8%) patients were switched from nevirapine to efavirenz upon diagnosis of TB. The results of




Figure 1. Efavirenz serum concentrations in TB/HIV-coinfecting Ugandan patients grouped according to *CYP2B6* 516 genotypes ($n = 166$). Line at 4 mg/L = upper limit of efavirenz reference range. The box extends from the 25th to the 75th percentile with a horizontal line at the 50th percentile (median). Whiskers extend to ± 1.5 times the IQR (height of the box) or the maximum/minimum value if there are no values (outliers) beyond these whiskers.

CYP2B6 516G>T genotyping for all 166 patients included in this analysis were as follows: 60 (36.1%) had genotype *CYP2B6* 516 GG, 81 (48.8%) had genotype *CYP2B6* 516 GT and 25 (15.1%) had genotype *CYP2B6* 516 TT.

A total of 333 efavirenz serum concentration measurements from 166 study participants were available for analysis, of which 176 (52.9%) were above the upper limit of 4 mg/L. The median time between last efavirenz dose and blood draw was 11.75 (IQR = 10.75–13.17) h. A total of 82 (49.4%) patients had at least one efavirenz concentration of >4 mg/L. The median efavirenz concentration among these patients was 7.1 (IQR = 5–12.5) mg/L, while those within the reference range had a median concentration of 2.1 (IQR = 1.2–3.0) mg/L. Thirty (18.1%) patients had at least one value below the lower limit of 1 mg/L, of which 24 patients had a single value <1 mg/L, 4 patients had two values <1 mg/L and 2 patients had three or more values below the reference range.

Patients with elevated efavirenz concentrations had a significantly lower median body weight [49 (IQR = 45–55.5) versus 53 (IQR = 48–58) kg, $P = 0.007$] and median haemoglobin concentration [10.2 (IQR = 8.7–11.4) versus 11 g/dL (IQR = 9.4–12.8), $P = 0.01$] compared with patients with efavirenz concentrations within the reference range. There was no significant difference in gender (male gender: 63.5% versus 59.8%, Pearson $\chi^2 = 0.366$), median age (34 versus 33 years, $P = 0.098$), median CD4 cell count (195 versus 131 cells/mm³, $P = 0.073$), median creatinine (0.65 versus 0.63 mg/dL, $P = 0.244$) and median ALT (20 versus 19.5 U/L, $P = 0.809$) between the groups.

In patients with a *CYP2B6* 516 TT genotype the median efavirenz serum concentration was consistently above the upper limit of 4 mg/L and significantly higher compared with GG/GT genotypes: *CYP2B6* 516 TT 9.6 mg/L (IQR = 7.3–13.3) versus *CYP2B6* 516 GT 3.4 mg/L (IQR = 2.1–5.1) and *CYP2B6* 516 GG 2.6 mg/L (IQR = 1.3–4.0) (Wilcoxon rank-sum test: $P < 0.0001$) (Figure 1). As shown in

Table 1. Univariable and multivariable logistic regression analyses with generalized estimating equations using 333 efavirenz serum concentration measurements from 166 patients

Variable	Univariable analysis			Multivariable analysis		
	OR	95% CI	P	OR	95% CI	P
Age (per 10 years older)	1.044	0.735–1.483	0.80	1.141	0.753–1.728	0.53
Male gender	0.563	0.316–1.001	0.050	0.535	0.287–0.996	0.048
Weight (per 10 kg higher)	0.662	0.454–0.963	0.031	0.665	0.454–0.974	0.036
CYP2B6 genotype			<0.0001			<0.0001
GG	1	(reference)		1	(reference)	
GT	1.624	0.856–3.081		1.720	0.888–3.331	
TT	27.89	7.560–102.9		28.944	7.121–117.6	

Table 1, CYP2B6 genetic variant was the only factor independently associated with elevated serum efavirenz concentration in the univariable and multivariable analyses (multivariable analysis: OR = 28.944, 95% CI = 7.121–117.64, $P < 0.0001$).

Discussion

For the majority of our study participants, serum efavirenz concentrations were within the reference range. However, almost half of our patients ($n = 82$, 49.4%) had at least one efavirenz serum concentration above the upper limit of 4 mg/L. The CYP2B6 516 TT genotype was the strongest predictor of efavirenz levels above the reference range, which is in line with previous studies.

Our study has a few limitations. Firstly, we did not systematically collect information on potential neuropsychiatric side effects in our cohort, so no conclusions can be drawn regarding whether the high efavirenz serum concentrations observed led to more side effects in this population. Secondly, the interpretation of the CYP2B6 genotype analysis is partly limited by the scope of testing (516G>T polymorphism only), as other polymorphisms may contribute to the high efavirenz serum concentrations observed in our study.

Genotype-guided dosing is not yet feasible in this setting. However, efavirenz dose reduction from 600 to 400 mg, as previously identified as an efficacious option for patients without TB coinfection,¹⁰ is expected to be feasible in TB/HIV-coinfected patients as well.¹¹ Whether this would result in a significantly reduced efavirenz exposure in individuals with the CYP2B6 516 TT genotype is, however, not certain. We conclude that physicians should be vigilant that efavirenz serum concentrations may be elevated in patients, despite concomitant anti-TB treatment including rifampicin, and that individualized care is warranted whenever possible.

Funding

This work was supported by the collaboration between the Infectious Diseases Institute in Kampala, Uganda and the University of Zurich in Switzerland. The collaboration is supported by the pharmaceutical companies AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck and ViiV Healthcare, as well as by Lunge Zürich, Shimadzu and the Swiss HIV Cohort Study. The funders had no role in the design, data collection, analysis or reporting of this study.

Transparency declarations

J. F. has received grants from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen Merck, ViiV Healthcare and Roche Diagnostics outside the submitted work. All other authors: none to declare.

References

- WHO. *Global Tuberculosis Report 2017*. 2017. <http://apps.who.int/iris/bitstream/handle/10665/259366/9789241565516-eng.pdf;jsessionid=BDAD6B8747597971C32DA54A82AB2C71?sequence=1>.
- WHO. *Treatment of Tuberculosis: Guidelines*. 2010. http://apps.who.int/iris/bitstream/handle/10665/44165/9789241547833_eng.pdf?sequence=1.
- Apostolova N, Funes HA, Blas-Garcia A *et al*. Efavirenz and the CNS: what we already know and questions that need to be answered. *J Antimicrob Chemother* 2015; **70**: 2693–708.
- Gutiérrez F, Navarro A, Padilla S *et al*. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. *Clin Infect Dis* 2005; **41**: 1648–53.
- Marzolini C, Telenti A, Decosterd LA *et al*. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. *AIDS* 2001; **15**: 71–5.
- Burger D, van der Heiden I, La Porte C *et al*. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. *Br J Clin Pharmacol* 2006; **61**: 148–54.
- Ngaimisi E, Minzi O, Mugusi S *et al*. Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4 β -hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. *J Antimicrob Chemother* 2014; **69**: 3311–9.
- Cohen K, Grant, A Dandara, C *et al*. The effect of rifampicin-based antitubercular therapy and cytochrome P450 2B6 genotype on efavirenz mid-dosing interval concentrations in a South African HIV-infected population. *Antivir Ther* 2009; **14**: 687–95.
- Dooley KE, Denti P, Martinson N *et al*. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection. *J Infect Dis* 2015; **211**: 197–205.
- ENCORE1 Study Group. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. *Lancet Infect Dis* 2015; **15**: 793–802.
- Mukonzo JK, Bisaso RK, Ogwal-Okeng J *et al*. CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population. *Pharmacogenomics* 2016; **17**: 603–13.

12 Sekaggya-Wiltshire C, Castelnuovo B, von Braun A et al. Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study. *BMJ Open* 2017; **7**: e014679.

13 Sekaggya-Wiltshire C, von Braun A, Lamorde M et al. Delayed sputum culture conversion in tuberculosis-human immunodeficiency virus-coinfected patients with low isoniazid and rifampicin concentrations. *Clin Infect Dis* 2018; **67**: 708–16.